EMA grants positive CHMP opinion for KYGEVVI® for Treatment of TK2d
EMA grants positive CHMP opinion for Kygevvi® for Treatment of TK2d International Mito Patients (IMP) and the global mitochondrial disease community […]
EMA grants positive CHMP opinion for Kygevvi® for Treatment of TK2d International Mito Patients (IMP) and the global mitochondrial disease community […]
Funding for the SynLeigh Project to Advance New Therapies for Leigh Syndrome IMP, Mitocon and Cure Mito Welcome ERDERA Funding International
IMP Annual Meeting 30-31 May 2026, France IMP’s Annual Meeting will take place 30–31 May 2026 at Brit Hotel Acropole,
Patients at the Heart of Research: IMP’s Role in the SIMPATHIC Drug Repurposing Project The SIMPATHIC project continues to make
Rare Disease Day 28 Feb 2026 Rare Disease Day is a global campaign that highlights the 300 million people worldwide
Amplifying Our Collective Voice: IMP at National and International Events As members of IMP, we are part of a global
International MELAS Consensus Meeting in Pisa: A Milestone for Patient Advocacy and Research From 28 to 30 November this autumn,
Mitochondrial Awareness Week 2025: 1.5million reached!! This September, our community united for World Mitochondrial Disease Week, a celebration of green lights,
First patient with rare muscle disease treated with own stem cells 9 November 2025 Maastricht UMC+ has, for the first
IMP Welcomes FDA Approval of First-Ever Treatment for TK2d International Mito Patient (IMP) is delighted to welcome yesterday’s approval by